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Plasmacytoid dendritic cells sense skin injury and promote wound
healing through type I interferons

Publication No. ______
Josh Gregorio, B.S., J.D.
Supervisory Professor: Michel Gilliet, M.D.

Plasmacytoid dendritic cells (pDCs) are a rare population of circulating
cells, which selectively express intracellular Toll-like receptors (TLR)-7 and
TLR-9 and have the capacity to produce large amounts of type I IFNs (IFN-α/β)
in response to viruses or host derived nucleic acid containing complexes. pDCs
are normally absent in skin but accumulate in the skin of psoriasis patients
where their chronic activation to produce IFN-α/β drives the disease formation.
Whether pDCs and their activation to produce IFN-α/β play a functional role in
healthy skin is unknown. Here we show that pDCs are rapidly and transiently
recruited into healthy human and mouse skin upon epidermal injury.
Infiltrating pDCs were found to sense nucleic acids in wounded skin via
TLRs, leading to the production of IFN-α/β. The production of IFN-α/β was
paralleled by a short lived expression of cathelicidins, which form complexes
with extracellular nucleic acids and activated pDCs to produce IFN-α/β in vitro.
In vivo, cathelicidins were sufficient but not necessary for the induction of IFNα/β in wounded skin, suggesting redundancy of this pathway. Depletion of
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pDCs or inhibition of IFN-α/βR signaling significantly impaired the inflammatory
response and delayed re-epithelialization of skin wounds.
Thus we uncover a novel role of pDCs in sensing skin injury via TLR
mediated recognition of nucleic acids and demonstrate their involvement in the
early inflammatory process and wound healing response through the production
of IFN-α/β.
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CHAPTER 1
INTRODUCTION

1

WOUND HEALING

The epidermis protects the body from the outside world and enables efficient
multicellular processes to occur through prevention of water loss across the
body surface, protection against ultraviolet radiation emitted by the sun, and
most importantly, the epidermis protects the body from daily assaults from the
outside environment including bacteria, fungi, and virus. The epidermis is
composed of two distinct layers, the stratified layer, which is composed of
flattened, differentiated anuclear, keratinocytes, and the basal layer, which is
composed of active differentiating keratinocytes and pluripotent stem cells (1,
2). The stratified layer is composed of many tiered layers of keratinocytes
whose main function is to provide a very tight barrier against the outside
environment. The basal layer is composed of keratinocytes with many
hemidesmisomal attachments to each other as well as to the basement
membrane (1, 2). The basement membrane marks the boundary between the
epidermis and the underlying dermis. The dermis on the other hand is a
collagen rich compartment populated by many tissue resident cells including
fibroblasts, T cells, macrophages, mast cells, and endothelial cells. In addition
hair follicle roots reside in the dermal compartment. The epidermis and dermis
collectively form the skin. Therefore, any damage done to skin has serious
ramifications if not resolved efficiently and expeditiously.

2

Wound healing is a multi-component process that involves many distinct cell
types in an ordered and efficient manner. Broadly, wound healing takes place in
distinct

overlapping

steps:

hemostasis,

inflammation,

proliferation

(angiogenesis, matrix remodeling), and epithelialization. Aberrant wound
healing can result in chronic injury such as ulceration or can result in fibrosis
such as keloid scars. Therefore, understanding the key steps as well as the
molecular cues is very important to understanding the functional aspects of
wound healing. Although much attention has been dedicated to wound healing
research over the past decade and a lot of information has been deciphered,
there remain many unknown elements in the complex process of wound
healing.

Assaults to the skin can take many forms and the resulting response will
depend on both the extent and nature of the trauma. For example, puncture
wounds such as an incisional wound will penetrate both the epidermis and
dermis. Typically puncture wounds can be stitched or stapled together and
allow for healing by Primary Intention. Primary Intention involves collagen
deposition, minimal migration of keratinocytes and typically heals efficiently and
fast (3). However open injury such as excisional wounds requires both a new
dermis and epidermis and involves new blood vessel formation, collagen
deposition and migration of keratinocytes to form both a new basal layer which
differentiates to form a new stratified layer. Additionally, trauma to the epidermis
alone such as thermal injury and chemical injury require keratinocyte migration
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from the wound margin and hair follicles to repair the injury. However, all dermal
wounds repair by connective tissue matrix deposition, contraction and
epithelialization.

Regardless of the nature of skin injury, I will provide a thorough, concise
summary of known players in wound repair, from both the perspective of cell
types involved as well as chemical mediators including cytokines, chemokines,
and non-immune modulators such as ATP, hypoxia, and lipids. Again although
the general scheme of wound repair has been elucidated, chronologically, the
exact timing and magnitude of the response will depend upon the severity and
type of injury which will not be discussed.

HEMOSTASIS

Most injuries will breach nearby blood vessel integrity causing blood
components

including

platelets,

fibrin,

fibronectin,

vitronectin

and

thrombospondin to be released into the injured tissue. Additionally, injury to the
blood vessel endothelium exposes collagen within the endothelium (3-7).
Platelets released from the blood bind to exposed collagen in both the dermis
and blood vessel endothelium through glycoprotein Ia/IIa receptors that kick
starts clot formation as well as sealing off the damaged blood vessel to prevent
hemorrhaging (8). von Willebrand factor (vWF), which also circulate in the
blood, binds to both platelets and collagen and this binding activates platelets
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(9, 10). Activated platelets release preformed dense and alpha granules. Dense
granules composed of adenine nucleotides, ionized calcium, histamine,
serotonin, and epinephrine are important in amplifying platelet aggregation and
vasodilation. Alpha granules are composed of chemotactic and growth factors
such as insulin-like growth factor 1 (IGF), platelet-derived growth factor (PDGF),
Transforming Growth Factor Beta

(TGF-β), chemokine-connective tissue-

activating peptide-III (CTAP-III), as well as coagulation proteins such as the
chemokine platelet factor 4 (CXCL4), thrombospondin, fibronectin and von
Willebrand factor (11-15).

Activated platelets also undergo morphological changes from a spherical to
stellate appearance. Calcium release from dense granules activates protein
kinase C and Phospholipase A2 resulting in increased affinity for fibrinogen
(16). Tissue factor expressed on the surface of tissue resident fibroblasts binds
to Factor VII released from the damaged blood vessel forming an activated
complex which further activates Factor IX and X. Activated Factor IX then
activates thrombin which then is armed to cleave soluble fibrinogen to fibrin
monomers (16). Fibrin monomers then polymerize to form a dense network of
insoluble fibrin fibers stabilized by Factor VIII (16).

Activated platelets bind fibrin through αΙΙ2/β3 receptors. The fibrin clot provides a
provisional matrix which not only seals the exposed epidermis from the outside
environment but also provides a conduit for infiltrating cells to traverse.
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Moreover, fibrinogen and fibrin contain specific binding sites for vascular
endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF-2 or
bFGF) which may play a role in facilitating homing of fibroblasts, endothelial
cells, and smooth muscle cells to the injured tissue (17-21). Fibrinogen
synthesis is positively regulated by both interleukin-1 beta (IL-1β) and
interleukin-6 (IL-6), cytokines important in the first few days of wound repair
(22).

INFLAMMATORY PHASE

Injured keratinocytes release preformed molecules including IL-1 and defense
peptides (cathelicidins, psoriasin, etc) into the extracellular matrix in addition to
secreting high levels of TGF-alpha (TGF-α), IL-6, IL-8 (human) and IL-10. IL-1
acts as a mitogen on dermal fibroblasts and positively regulates fibroblast
homing and proliferation (23-26). The human cathelicidin, LL-37, has been
shown to possess both, direct, antimicrobial properties as well as being
chemotactic for neutrophils (27, 28). Additionally, in vitro, LL-37 can interact
with self-nucleic acids to activate both plasmacytoid and myeloid dendritic cells
(29-30). TGF-α has a strong autocrine effect on wound edge and hair follicle
resident keratinocytes resulting in keratinocyte hyperproliferation (25).

Further secretion of TGF-α and IL-6 by wound edge keratinocytes helps
mobilize keratinocytes to the wounded epidermis early to begin the process of
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re-epithelialization. KGF, IL-6, GM-CSF are also rapidly induced by fibroblasts
upon exposure to keratinocyte derived IL-1. KGF binds to FGFR2IIIβ receptors
on keratinocytes resulting in keratinocyte proliferation (25). Additionally, IL-6
has a pleotrophic role in wound healing and acts early by stimulating
keratinocyte proliferation. IL-6-/- mice have a delayed wound healing response
characterized by reduced re-epithelialization, leukocyte infiltration, angiogenesis
and collagen accumulation (31).

Dendritic Epithelial T cells (DETC) comprise a small population of γδ T cells that
reside in the epidermis. Found in mouse, DETC’s are in direct contact with
keratinocytes and function in wound repair as well as tumor surveillance (23). In
human, epidermal T cells possess αβ T cell receptors but not a dendritic
phenotype and are much less abundant than in mouse (32). The γδ TCR
recognizes an unidentified antigen released by damaged or stressed
keratinocytes. DETC's produce keratinocyte growth factor-1 (KGF-1) and KGF2, insulin-like growth factor-1 (IGF-1), interleukin-2 (IL-2), interferon-gamma
(IFN-γ), and lymphotactin (23). TCRg-deficient mice exhibit a delayed wound
closure upon full thickness injury due to delayed keratinocyte hyperproliferation
resulting from the absence of DETC derived KGF-1 and KGF-2 (23).
Additionally, activated DETC induce keratinocytes to produce hyaluronan which
is used by macrophages to migrate to the injured skin. Injured TCRg-deficient
mice failed to induce macrophage infiltration to the upper dermis (near the
wound), further providing a critical role for DETC's in wound repair (23).
7

Concomitant with signals from injured keratinocytes and DETC's the thrombus,
composed of a mesh of activated platelets and polymerized fibrin, provides a
rich source of growth factors and chemotactic molecules. PDGF initiates the
chemotaxis of neutrophils, macrophages, and stimulates the mitogenesis of
smooth muscle cells and fibroblasts (3).

CTAP-III is cleaved to neutrophil-

activating peptide-2 (NAP-2; CXCL7) by neutrophils attached to the thrombus
(33) and attracts blood circulating neutrophils through CXCR2 engagement.
TGF-β released by activated platelets attracts macrophages and stimulates
them to produce fibroblast growth factor (FGF), PDGF, tumor necrosis alpha
(TNF-α) and interleukin-1 (IL-1).

Additionally, TGF-β acts on fibroblast and

smooth muscle cells to express collagen and collagenase (34-37).

Tissue resident mast cells cluster around blood capillaries and sense injury
through the Complement proteins C3a and C5a as well as TGF-β and IL-8
(human), and release granules containing histamine, enzymes, and other active
amines (38, 39). Additionally, mast cells release small lipids such as platelet
activating factor (PAF), leukotrienes C4/D4, and prostaglandins which serve to
increase vasodilation, blood vessel permeability, upregulation of adhesion
molecules on endothelial cells, survival signals to tissue cells, and smooth
muscle contraction which facilitates the egress of inflammatory cells, most
notably, neutrophils into the damaged tissue (38, 39).

Mast cells can also

antagonize coagulation through release of tryptase which interferes with the
ability of thrombin induced fibrin formation. Also, mast cells are recruited to the
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provisional matrix through monocyte chemotactic protein-1 (MCP-1) released
by tissue resident keratinocytes and endothelial cells and upregulate
interleukin-4 (IL-4) expression during the later stages of the inflammatory
response to shutdown expression of TNF-α and IL-8 (38-41). Moreover, mast
cells play an important role in later phases of wound repair such as granulation
and angiogenesis.

Neutrophils arrive to injured skin within minutes and comprise roughly 50% of
all cells for the first few days post injury (Figure 1). Expression of CXCR2 by
neutrophils enables them to respond to macrophage inflammatory protein-2
(MIP-2) and keratinocyte-derived chemokine (KC) in mouse (IL-8 and
Melanoma growth-stimulatory activity/growth-related protein-α (MGSA/GROα),
respectively, in humans). KC produced by dermal fibroblasts and endothelial
cells is the main source of neutrophil chemotaxis for the first 6 hours after injury
(42). On the other hand, MIP-2 released by infiltrating neutrophils and
monocytes is responsible for continued neutrophil chemotaxis. Continued
release of MIP-2 occurs if an infection is present, otherwise, neutrophils cease
to infiltrate after the first two days of injury (37, 42). Additionally, murine but not
human neutrophils express CCR1 that recognizes MCP-1, macrophage
inflammatory protein 1 alpha (MIP-1α, and regulated on activation normal T
expressed and secreted protein (RANTES). Interestingly, CXCR2-deficient mice
exhibit delayed wound healing upon excisional injury, which is mainly attributed
to the lack of neutrophil infiltration (37, 43). Although, expression of CCR1 by
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neutrophils is thought to attract some neutrophils, CXCR2 expression is vital for
a sufficient neutrophil response. However, normal levels of monocyte infiltration
occur in CXCR2-deficient mice which clearly suggest that although, classically,
neutrophils appear to the injured tissue prior to monocytes, their responses are
independent of one another.

Although the historic function of infiltrating neutrophils was to clear bacteria and
cellular debris, it has recently been shown that neutrophils contribute much
more dynamically to the wound healing process. Upon arrival to the injury
neutrophils are the predominant source of TNF-α, IL-1 and IL-8 in human (44,
46). Neutrophil activity is most prominent during the first 48 hours after injury
and precipitously decline throughout the remainder of the wound repair process.
Neutrophils stop infiltrating through many processes including negative
regulation of CXCR2 expression by increasing levels of TNF-α, IL-10,
interferon-g-inducible protein-10 (IP-10; CXCL10) and other inhibitory ligands
expressed in high concentrations. Infiltrating macrophages phagocytose
remaining neutrophils beginning around day 4.
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Figure 1. Wound healing during Inflammation phase (3 days after injury).
Growth factors thought to be necessary for cell movement into the wound
are shown (Singer, (56), Reprinted with permission from Massachusetts
Medical Society).
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The presence of monocytes at day 3 marks the near end of the inflammatory
response and the beginning of the proliferation phase (9, 15). Circulating blood
monocytes are attracted to injured tissue by degradation products of the
extracellular matrix such as fragments of collagen and fibronectin as well as the
chemokines MCP-1, MIP-1α, RANTES released by endothelial cells (15).
Upregulation of adhesion molecules on the blood vessel endothelium promote
monocyte extravasation from circulation and monocytes differentiate into
macrophages upon engagement of Mac-1 integrin receptor (CD11b) to
fibronectin within the provisional matrix. Macrophages release growth factors
such as TNF-α, IL-6, IL-1, IGF, and FGF in addition to facilitating breakdown of
the fibrin clot by stimulating fibroblast and endothelial cell mobilization to the
clot through release of TGF-β and PDGF which enable degradation of the fibrin
clot and replacement with collagen. Moreover, macrophages are thought to be
the primary source of monokine induced by interferon-g (Mig, CXCL9), IP-10,
and macrophage-derived chemokine (MDC, CCL22) that are associated with
lymphocyte accumulation in the wound and marks the shift from a proinflammatory response (TNF-α/IL-1) to a IFN-γ one (15, 46).

PROLIFERATION PHASE

Concomitant with PDGF and TGF-β released in the provisional matrix, fibrin and
fibronectin activate neighboring fibroblasts to upregulate α3β1, α5β1, αvβ1,
αvβ3, and αvβ5 integrins, proliferate, and migrate to the injury (4). Collectively,
12

these signals cue both fibroblasts and endothelial cells to upregulate expression
of the serine proteases tissue plasminogen activator (tPA, endothelial cells) and
urokinase plasminogen activator (uPA, fibroblasts) to cleave plasminogen to the
active plasmin (Figure 2). Fibrin is a cofactor for tPA while uPA recepter (uPAR)
expression on fibroblasts serves as a cofactor for uPA. Additionally, fibroblasts
must migrate to the injury and do so by clearing a way through breakdown of
the provisional matrix through interstitial collagenase-1 and -3 (MMP-1 and
MMP-13, respectively), the 72-kDa gelatinase A (MMP-2), and stromelysin
(MMP-3) (5). Plasmin degrades the provisional matrix through fibrin proteolysis
and enables fibroblasts to synthesize a new collagen matrix and endothelial
cells to form new blood vessels to the injured tissue.
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Figure 2. Wound healing during Proliferation phase (5 days after injury).
Proteinases thought to be necessary for cell movement are shown (Singer
(56), Reprinted with permission from Massachusetts Medical Society).
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Fibroblasts are the predominant cell in the wound during the proliferative phase
and play a critical role by synthesizing new collagen. TGF-β serves a vital role
during the proliferative phase as it stimulates fibroblast proliferation, promotes
transcription of the genes for collagen, proteoglycans and fibronectin, inhibits
secretion of proteases responsible for the breakdown of the matrix and
stimulates the protease inhibitor tissue inhibitor of metallo-protease (TIMP) (3).
Fibroblasts attach to the provisional fibrin clot after migration to the wound and
begin proteolysis of the fibrin clot and then switch functions to produce high
amounts of Type I collagen. Collagen synthesis is then halted when sufficient
collagen has been deposited into the extracellular matrix.

During collagen synthesis, there is an important step involving hydroxylation of
proline and lysine residues (47). Hydroxylation allows collagen to form its
characteristic triple helical structure and hydroxyproline residues stabilize the
helical conformation. Procollagen is then secreted into the extracellular spaces
where it is further processed by cleavage of the N and C- terminal peptides
(47). Collagen undergoes further modifications to strengthen it. Lysyl oxidase,
found in the extracellular matrix, further cross-links collagen strands to give
more rigidity and tensile strength to the dermis. Additional intrastrand and
interstrand cross-links form over time that further increases collagens strength
and stability (47, 48). Collagen, on a gram per gram basis, has the same tensile
strength as steel. Collagen remodeling also occurs during the remodeling phase
which, classically, is the last phase of wound repair. Specific collagenases from
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fibroblasts, neutrophils, and macrophages are capable of cleaving collagen
through all three chains of the triple helix, which is further digested by other
proteases (47, 48).

TGF-β1 also stimulates fibroblasts to differentiate into myofibroblasts, key cells
involved in connective tissue remodeling characterized by high expression
levels of the contractile molecule alpha smooth muscle actin (α-SMA) (49).
However, myofibroblast differentiation is dependent upon the fibronectin splice
variant ED-A in addition to TGF-β1 (50). Also, TGF-β can induce α-SMA
synthesis through SMAD-dependent and -independent processes (51, 52). αSMA expression and enhanced contraction are restricted to later phases of
wound healing despite high levels of TGF-β1 during the early stages due to
negative regulation of α-SMA expression by the inflammatory molecules IL-1
and IFN-γ.

Although myofibroblasts serve a prominent role in wound contraction,
myofibroblasts also synthesize significant levels of ECM components and
matrix degrading enzymes including collagens of types I, III, IV, and V as well
as the glycoprotein tenascin-C (53). Tenascin-C has been shown to recruit
fibroblasts and to injured tissue and to promote their differentiation into
myofibroblasts (54).

Not surprisingly, myofibroblast are implicated in

hypertrophic scarring and fibrosis development and persistence activity within a
fibrotic lesion leads to elevated scarring and functional impairment of the
16

affected organ. Tight regulation of myofibroblast activity is necessary to prevent
overscarring of the ECM. Recently, it has been shown that in addition to
keratinocyte derived IL-1 secretion, growth hormone suppresses TGF-β induced
myofibroblast development and consequently reduced fibroblast contractile
activity (49).

Vascular endothelial cells in and around the injured tissue proliferate to provide
new vasculature to the healing wound. Neovasculature also known as
angiogenesis is a tightly regulated process and occurs concurrent with
fibroblast and macrophage infiltration. Angiogenic factors released by
keratinocytes and macrophages provide the necessary signal for vascular
endothelial cells to form new capillaries from existing blood vessels. Sprouting
capillaries express αvβ3 integrin at their tips induced by VEGF and FGF that
allows capillaries to migrate through the fibrin/fibronectin rich clot (10).
Fibroblast mediated proteolysis of the ECM is necessary for endothelial cell
movement into the injured tissue and macrophages provide pro-angiogenic
molecules. However, excess granulation and delayed macrophage infiltration
inhibit angiogenesis (10).

Glu-Leu-Arg (ELR) containing CXC chemokines are potent inducers of
angiogenesis (15). ELR+ CXC chemokines include IL-8, GRO-α, GROβ(CXCL2), GRO-γ (CXCL3), CTAP-III, β-thromboglobulin, and NAP-2, which
are released by macrophages and fibroblasts in the granular tissue (55).
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Additional angiogenic factors include VEGF, KGF-1 KGF-2, TGF-β, angiogenin,
angiopoieitin, and mast cell tryptase. Angiopoietins belong to the VEGF family
and are thought to be the only growth factors specific for vascular endothelium.
Two important members include the angiogenesis agonist, Angiopoietin-1 and
Angiopoietin-2, a natural antagonist (10). As the provisional matrix is replaced
by Type I and III collagen (scar tissue) αvβ3 integrin expression is lost and
angiogenesis ceases. Moreover, many of the newly formed capillaries undergo
apoptosis during scar tissue formation. Interestingly, the inflammation induced
molecules; Platelet factor-4 (PF4), IP-10, MIG inhibit angiogenesis and thus
further demonstrate the spatio-temporal aspects of wound healing (10).

RE-EPITHELIALIZATION

Upon injury, wound edge keratinocytes as well as neighboring hair follicular
keratinocytes migrate across the provisional matrix to form a monolayer over
the denuded epidermis. Mitogenic signals from DETC's, dermal fibroblasts, and
keratinocytes induce basal keratinocytes to dissolve α6β4 integrin attachments
to the basal layer and to induce the expression of α5β1 and αvβ6
fibronectin/tenascin receptors, αvβ5 vitronectin receptor, and to rearrange α2β1
collagen receptors (1). Upregulation of these integrins allows leading edge
keratinocytes to migrate across or through the injured dermis. Once the
migrating keratinocytes form a monolayer over the injured dermis they
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downregulate expression of α5β1 and αvβ5 integrins, stop migrating, and
undergo differentiation to form a new stratified epidermis (Figure 3) (1).

19

Figure 3. Re-epithelialization of injured porcine skin. Leading
edge keratinocytes at wound margin forming epidermal monolayer
(basal layer, black arrows), E: epidermis, clot: fibrin provisional
matrix, granulation tissue: neo-collagen rich dermis. (Singer et al.
(56), Reprinted with permission from Massachusetts Medical
Society).
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CONCLUSION

Wound healing is a highly dynamic process, includes the participation of many
diverse cell types, and dependent upon many factors. Too much inflammation
can lead to chronic ulceration while too little can lead to excessive scarring.
Although, wounds heal remarkably, fast healing is imperfect and the resultant
scar tissue is both weaker and less organized than undamaged dermis. In
summary, epidermal injury causes both epidermal constituents, namely,
keratinocytes and DETCs, as well as dermal resident cells, principally, platelets,
fibroblasts, endothelial cells, neutrophils, monocytes/macrophages and mast
cells to undergo cooperative activation to repair the injury to limit trauma as well
as to resupply nutrients and blood flow.
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PLASMACYTOID DENDRITIC CELLS

pDCs have a fascinating history beginning with their initial identification in 1958
by Lennert and Rammele (57) who reported plasma like cells located within the
T cell area in human lymph nodes. These cells lack B cell and plasma cell
markers and were initially called T-associated plasma cells. Later, research
efforts by Feller in 1983 determined that these cells expressed CD4 but lacked
immunoglobulin and B-cell antigen (58) and were renamed plasmacytoid T cell.
It was postulated that these cells performed T cells functions and produce T cell
cytokines. However, in 1988 Facchetti determined that these cells do not
express CD3, a vital component of the T cell receptor complex expressed by all
T cells. Moreover, these cells expressed myeloid antigens CD36 and CD68 as
well as MHC Class II molecules. Based on these observations it was thought
that these cells were more like monocytes than T cells and again, these cells
were renamed to plasmacytoid monocytes (59). Much chaos ensued as the
field was divided as to whether these cells were a subset of monocytes or were
a new cell type. This led to additional efforts which were directed at identifying
these cells both phenotypically and functionally. In 1994, O’Doherty identified a
CD11c-

HLA-DR+ dendritic cell population from human peripheral blood

characterized by low MHC Class II expression and low T cell stimulatory
capacity (60). However, upon culture with monocyte conditioned medium these
cells upregulated MHC Class II expression and assumed a dendritic cell
morphology (60). Concomitantly, research efforts led by Liu identified two types
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of CD4+CD3- cells located in different areas of human tonsil tissue (61, 62).
Intriguingly, CD4+CD3- cells located within the germinal center expressed
CD11c and were potent at activating naïve CD4 T cells and germinal center B
cells. Conversely, CD4+CD3- cells located near high endothelial venules within
T cell rich areas lacked CD11c expression and were matured when stimulated
with IL-3 or IL-3 plus CD40 ligand (63).

CD4+CD3-CD11c+ cells were

classified within the DC lineage while CD4+CD3-CD11c- cells were classified
as pre-DC (61-63). In 1997 Liu’s lab successfully isolated pure CD11c- pre-DC
from tonsillar tissue (63). Isolation of pure CD11c- pre-DC allowed further
characterization and classification of these cells. CD11c- pre-DC were
subsequently found to be unrelated to monocytes as they lacked phagocytic
activity in addition to not expressing monocyte antigen and were renamed
plasmacytoid dendritic cells (pDCs). pDCs were further classified as type 2
precursor DC (DC2) based on their ability to promote TH2 T cell differentiation,
whereas monocytes or myeloid DCs were classified as type 1 DC (DC1) based
on their ability to favor TH1 T cell differentiation (64). However, later studies
showed that both DC1 and DC2 cells exhibit flexibility in inducing both TH1 and
TH2 responses and that the particular T cell response is mediated by both the
environmental cytokine milieu as well as DC interaction (65).

While the identification and investigation of CD11c+ and CD11c- DCs were
being studied, an additional field of immunological research was focused on the
identification of a Type I Interferon producing cell. In the late 1970’s it was
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discovered that upon viral challenge there was a peripheral blood cell
responsible for strong Type I Interferon induction (59). Although most cells are
capable of producing Type I Interferon, this unidentified cell was able to
produce 10-1000 times more Interferon-alpha (IFN-α) than any other cell (66)
and was called Professional Interferon Producing Cell or IPC. These cells were
initially thought to be NK cells as NK cells were found to be activated by IFN-α
in response to viral infection (67, 68). With the development of specific
monoclonal antibodies for NK cells, T cells and monocytes/macrophages it was
found that IPC did not express classical markers for these cells (69, 70).
Investigation over the next few years revealed little insight into the cell identity
of IPC. However, a breakthrough study in 1996, demonstrated that HSV
challenge

prompted

strong

intracellular

IFN-α

induction

in

CD4+DR+CD45RA+CD11c-CD11b-CD14-CD13-CD33-CD16-CD80-CD86surface expressing cells (71). In 1999, Siegel (72) demonstrated that pDC are
IPC (73, Table 1) that was confirmed by Cella (74).
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pDC/IPC

Monocytes

CD11c+ immature DC

Phenotype
CD11b
CD11c
CD13
CD14
CD4
TLR7
TLR9
BDCA2
IL-3R

–
–
–
–
++
++
++
+
+++

+
+
+
+
+
+
–
–
+

+
+
+
+
+
++
–
–
+

Function
IFN-α/β
IL-12
Phagocytosis

+++
–
–

+
++
++

+
++
++

Table 1. Human DC Phenotype Comparison. pDCs can be
differentiated from monocytes and other DC based on the absence of
CD11c expression, common myeloid marker expression as well as
having strong expression of BDCA-2 and IL-3 Receptor. Functionally,
pDC produce large amounts of Type I IFN, lack IL-12 production and are
unable to phagocytose (73).
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In mouse, pDCs were identified as having different surface marker expression
than human pDC. Murine pDCs were classically defined as CD11c+B220+Gr1+CD45RbhighCD11b- cells (75-77). However, murine pDCs also express
PDCA-1 (78) and Siglec H (79) (73, Table 2).

Under steady state conditions, pDCs are present in the blood stream and
secondary lymphoid organs, but are normally absent from most peripheral
tissues including the skin (80, 81). pDCs can, however, infiltrate the skin
infected by viruses including varicella zoster virus (82), human papillomavirus
(83), and herpes simplex virus (84). These skin-infiltrating pDCs were found to
produce IFN-α/β, which is consistent with the ability of viruses to infect pDCs
and deliver their nucleic acid cargo into intracellular TLR 7/9 compartments of
pDCs.
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Phenotype
CD8
CD11b
CD11c
CD4
B220
Siglec H
Ly6c
PDCA-1
DEC-205
Function
IFN-α/β
IL-6
IL-12
IFN-γ
CD8 T cell
ccrocross-

pDC/IPC

CD8a+CD4–

CD8a–CD4–

CD8a–CD4+

+/–
–
+
+/–
+
+
+
+
–

+
+
–
–
–
–
–
+

–
+
+
+
–
–
–
–
+/–

–
+
+
+
–
–
–
–
–

+++
++
+

–
–
–
–
–

–
–
–
–
–

+++
+
+
–
–

Table 2. Mouse DC Phenotype Comparison. pDCs can be differentiated from
other DC based on strong expression of B220, Siglec H, PDCA-1 and Ly6c.
Functionally, pDC produce large amounts of Type I IFN and generate low IL-12
production (73, 78, 79).
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pDCs are a rare population of circulating cells comprising only 0.2 to 0.8% of
peripheral cells (85). pDCs selectively express endosomal restricted Toll-like
receptors (TLR)7 and TLR9 (86), which recognize single-stranded viral RNA
and DNA transported into endosomal compartments by the virus infecting the
cell (87-90). IFN-α/β produced by pDCs was shown to be critical in inhibiting
viral replication but also to contribute to the induction and expansion of an
antiviral immune response by activating memory T cells, B cells, and NK cells
(91, 92).
Surprisingly, large numbers of pDCs have also been found in the skin of
patients with psoriasis (80, 81, 93), a chronic inflammatory disease of the skin
mediated by autoimmune T cells. Here, pDCs are chronically activated to
produce IFN-α/β, a process that triggers the activation and expansion of
autoimmune T cells leading to the epidermal hyperproliferation and the
formation of psoriasis. We have recently found that pDC activation in psoriatic
skin is driven by the human cathelicidin antimicrobial peptide known as LL37
(29). LL37 was found to convert otherwise inert extracellular host-derived (self)
nucleic acids, into a potent trigger of pDC activation by forming a complex with
the self-RNA and self-DNA and by transporting them into intracellular TLR 7
and TLR 9 compartments (30, 29). The cathelicidin peptide is usually not
expressed in healthy skin but is continuously overexpressed by keratinocytes of
psoriatic skin, providing an explanation for the chronic activation of pDCs in
psoriasis (29). Interestingly, the expression of cathelicidin peptides can be
transiently induced in keratinocytes by common skin injury (94, 95).
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ANTI-MICROBIAL PEPTIDES (AMPS)

AMPs are evolutionarily conserved host defense peptides which possess
potent, broad spectrum antibiotic properties (96). Cationic AMPs are relatively
short peptides (12-50 AA) and comprise two families, the cathelicidins and the
defensins. Only one member of the cathelicidins has been identified to date;
LL37 in human and CRAMP in mouse (97-99). The defensins, composed of
alpha and beta families are produced by neutrophils, keratinocytes and paneth
cells in human and epithelial cells, respectively in mice (96). Cationic AMPs
have a net positive charge and are amphipathic while possessing either a
predominant alpha helical or β-sheet structure (96). Cathelicidins and defensins
are expressed by keratinocytes and are important contributors to host defense
(100-104). Upon epidermal injury keratinocytes release pro- peptides which are
subsequently cleaved to reveal active peptides (105). Moreover, these peptides
are capable of forming pore-forming complexes in microbial cell wall resulting in
cell lysis. Additionally, host cells are protected from autolysis as the cationic
AMPs selectively bind to microbial cell membranes (96). Cathelicidins has been
found to contain chemotactic properties as cathelicidins can directly mediate
neutrophil, macrophage, and T cell migration (104).

AMP release is also positively regulated by a subset of T cells (104). In
psoriasis, continued inflammation amplifies cathelicidin, defensin, and psoriasin
peptide production by keratinocytes (104, 105). Extremely elevated levels of LL-
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37 and psoriasin have been measured in chronic psoriatic plaques compared to
healthy or uninvolved skin (105). This dysregulated response helps maintain the
inflammatory state and recent evidence suggests that continued LL-37
production can provide a potent stimulator for pDC activation mediated through
associated with nucleic acids and uptake and triggering of TLR 7 and TLR 9
(30, 29).
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CLINICAL RELEVANCE

There are numerous skin diseases which are due to or result in dysregulated
immune responses such as psoriasis, contact dermatitis and atopic dermatitis
(106). Psoriasis is the most understood skin disorder and provides a good
model to evaluate pDC involvement in the pathogenesis of this inflammatory
disease. Psoriasis is a chronic inflammatory disease affecting 1-3% of the
global population (107, 108). Phenotypically, psoriasis is characterized by
raised,

scaly,

erythematous

plaques.

Immunologically,

psoriasis

is

characterized by chronic activation of myeloid dendritic cells and autoreactive T
cells (106). mDC once activated present self-antigens to T cells which then
drives the pathogenesis of psoriasis by differentiating into TH1 and TH17
effector cells (106, 108). The exact timing and location of this process is still
under debate. One school of thought is that mDC and other dermal DC migrate
to skin draining lymph nodes upon activation and present self-antigens to naïve
T cells (107). Auto-reactive T cells then migrate into the psoriatic dermis.
However, Th1 differentiation requires IL-12 and TH17 requires IL-23 along with
the appropriate MHC ligands. Sources of IL-12 and IL-23 in the lymph node
may be attributed to the activated DC presenting the antigen to the T cell.
Alternatively, activated DC present antigen to dermal resident T cells, which
then differentiate into TH1 or TH17 cells (107). Recent reports have
demonstrated that activated mDC can produce IL-12 and IL-23 in the
dermis.TH1 cells produce IFN-γ while TH17 cells produce IL-17 and IL-22. TH1
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and TH17 cells then propagate the inflammatory cycle by stimulating
proliferation and activation of keratinocytes to produce antimicrobial peptides
such as LL-37, B-defensin 1, B-defensin 2, S100A7 and S100A9. Keratinocytes
also produce IL-1β and neutrophil chemotactic molecules CXCL1, CXCL3,
CXCL5 and CXCL8 (107, 109).

Recent progress in understanding the initiation of the inflammatory reaction
witnessed in psoriasis has elucidated pDC as an important trigger. Local
epidermal or dermal injury triggers the Koebner phenomenon that results in new
lesions where the injury occurred. It is thought that the initial injury disrupts
keratinocytes at the site of injury. In response to the injury keratinocytes then
release antimicrobial peptides such as LL-37 as well as additional cytokines.
Local injury also causes cell damage resulting in apoptosis which releases
apoptotic DNA into the extracellular space. Recently it was shown that pDCs
are important mediators in the initiation of the inflammatory cascade in psoriasis
(93). pDCs become activated in the injured skin and release IFN-α.
Neutralization of pDCs through BDCA-2 specific antibodies as well as anti-IFNα antibody completely abolished development of the psoriatic plaque. More
recently, our group demonstrated that pDCs can bind LL-37/self-DNA and LL37/self-RNA to become activated to produce large amount of IFN-α (29, 30).
Potentially, LL-37 released by damaged keratinocytes can bind endogenous
DNA which then becomes a potent stimulus for pDC activation. Additionally, LL37/self-RNA can activate mDC to produce IL-12 and IL-23 (30). IFN-α then
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drives mDC maturation which promotes more efficient antigen presentation to
auto-reactive T cells. Interestingly, pDC are absent from chronic psoriatic
plaques indicating that once the inflammatory cycle is initiated positive feedback
loops between mDC, T cells and keratinocytes maintains psoriatic pathogenesis
(107, 109). In human pDC constitute less than 1% of dermal lymphocytes
whereas pDC are absent in murine dermis under steady-state conditions.
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Basis for Dissertation

Some of main questions yet to be answered in autoimmune skin disorders such
as psoriasis are 1) what drives pDCs infiltration into psoriatic skin, 2) why don’t
pDCs infiltrate into uninvolved skin in psoriasis patients, 3) why do psoriatic
patients have unabridged pDCs activation whereas non-psoriatic patients don’t
develop psoriasis, 4) what role do pDCs play in skin injury in non-psoriatic skin
and 5) what mechanism counters pDCs activation to prevent uncontrolled
inflammation?

My research addresses the role of pDCs in normal skin injury. By normal I
mean non-diseased, steady-state skin. My research has shed light onto the
basis of pDC involvement in skin injury as well as the consequence of wound
healing without pDC involvement. I uncovered a new role for pDC in sensing
injury that will hopefully provide new strategies for therapeutic intervention in
autoimmune skin disorders such as psoriasis.
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CHAPTER 2
MATERIALS AND METHODS

35

MICE
Wild-type BALB/cJ, C57Bl/6, or 129SV/J mice and TLR7-/- (B6.129S1Tlr7tm1Flv/J) mice were purchased from The Jackson Laboratory. MyD88-/mice were kindly provided by S. Akira (110), IFNAR-/- mice (111) were provided
by W. Overwijk. Cramp-/- mice were from the lab of Richard L Gallo (112). All
animal experiments were conducted on 6-14 week old mice. Animals were
maintained and bred in specific pathogen free facilities. All animal experiments
were approved by the Institutional Animal Care and Use Committee of the
University of Texas M.D. Anderson Cancer Center.

REAGENTS
The

synthetic

mouse

cathelicidin

(GLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPEQ),

peptide
and

the

CRAMP
corresponding

scrambled control (LLGQNGKFKIREPPIQKVKGIQEKEFGLKQKLKG) were
obtained from AnaSpec. For in vivo experiments 200 µg of the peptides were
injected into the dermis of the upper dorsum of shaven and depilated mice. For
in vitro pDC stimulation 30 µM of the peptides were used. The TLR 7/9 inhibitor
IRS

954

(5'-TGC

TCC

TGG

AGG

GGT

TGT-3',

phosphorothioate

oligodeoxynucleotide) was a kind gift of F. Barrat, Dynavax Technologies. The
TLR 9 inhibitor IRS 869 (5'-TCC TGG AGG GGT TGT-3', phosphorothioate
oligodeoxynucleotide) was purchased from Integrated DNA Technologies. For
inhibition of TLR9 or TLR7 and TLR9 in vivo, intradermal administration of IRS
869 and 954 were used 24 hours and 4 hours prior to the skin injury.
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MECHANICAL INJURY OF MOUSE SKIN
Mice backs were shaven and depilated (Veet, Reckitt Benckiser) immediately
prior to injury. Mechanical injury was then applied by tape stripping, using 20
strokes of transparent tape (Scotch, 3M) across the back. For full-thickness
injury, mice dorsal skin was shaven, cleaned with 70% ethanol, and a 3 mm
punch biopsy (Acuderm) was applied to remove skin (care was taken to ensure
excision was restricted to a depth of the fascia layer). Calipers were used to
monitor wound closure over a 14-day period.

DEPLETION EXPERIMENTS
pDC depletion was carried out using a combination of two anti-BST antibodies
(PDCA1, Miltenyi Biotec, Clone: JF05-1C2.4.1) and mAb 927 (kindly provided
by Marco Colonna, Washington University School of Medicine. 0.5 mg of each
antibody was injected, intraperitoneally, 48 hours and 24 hours before injury.
Rat IgG antibodies were injected into control mice. Depletion of pDCs was
monitored in the speen by flow cytometry and was found to be most efficient
when the combination of the antibodies was used. Neutrophil depletion was
conducted using an anti-Ly6G specific antibody (Bioxcell, clone 1A8). 1 mg of
anti-Ly6G or whole rat IgG was injected, intraperitoneally, into mice at 24 hours
and 4 hours before injury.
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MECHANICAL AND CHEMICAL INJURY OF HUMAN SKIN
Mechanical injury of human skin was induced by application of 10 strokes of
cellophane tape across healthy skin of 7 human volunteers. Biopsies were
taken before (uninjured) and 24 hours after tape stripping (injured). The
specimen was snap frozen and stored at -80°C before immunohistochemical
and gene expression analysis was performed. Chemical injury of human skin
was induced by treatment of healthy skin of human volunteers with the chemical
irritant Sodium Lauryl Sulphate (SLS) (Merck KGaA, Darmstadt, Germany) at
1% in water as described previously (113). Briefly, SLS was applied in large
Finn Chambers to the skin on the back of the patients, before biopsies were
taken. Specimens were immediately snap frozen and stored at -80°C before
immunohistochemical and gene expression analysis was performed. All human
studies were performed at the Skin and Allergy Hospital, Helsinki University
Central Hospital, Helsinki, Finland and approved by the local ethics committee
(Helsinki-Uusimaa Hospital District Ethics Committee).

GENERATION AND ANALYSIS OF DERMAL SINGLE CELL SUSPENSIONS
Injured skin was excised, minced and digested with 1 mg/ml Dispase (Sigma)
for one hour at 37°C and the epidermis was manually removed with forceps.
The dermis was removed to a clean culture plate and incubated with 1 mg/ml
Collagenase (Gibco) for two hours to generate a single-cell suspension.
Leukocytes were counted using trypan blue exclusion. Cells were treated for 20
min with anti-CD16/CD32 to block non-specific binding, followed by the addition
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of the following antibodies at 10 µg/ml final concentration for 20 min: antiPDCA-1 FITC (Miltenyi Biotec), anti-Siglec-H-FITC (eBioscience) anti-CD11cPE, anti-B220-APC, anti-IA/IE-PE, anti-CD11b-FITC, anti-Gr-1-PerCp-Cy5.5
and anti-CD3e-APC (all BD). Cells were washed twice and acquired on a
FACSCaliber and analyzed using FlowJo software.

IMMUNOHISTOCHEMISTRY AND IMMUNOFLUORESCENCE
Mouse skin tissue was excised, embedded in OCT (Tissue-Tek) and frozen
immediately on dry ice. 8 µM frozen sections were cut and stained with antiSiglec H (3H3 clone) followed by Horseradish Peroxidase labeled goat anti-rat
IgG and a color development step with Aminoethylcarbazole. For K6 staining,
frozen sections were stained with a purified rabbit anti-mouse keratin 6 antibody
(Covance) and subsequently stained with Alexa 546 labeled goat anti-rabbit IgG
(H+L) (Molecular Probes). For detection of pDCs in human skin tissue we used
an anti-BDCA2 antibody (Miltenyi Biotec) according to the previously described
protocol (29).

REAL-TIME PCR ANALYSIS
All excised tissue was immediately saturated in RNAlater (Ambion) and stored
at -20°C until RNA was isolated. Skin was homogenized using a Tissue-Miser
device (Fisher) in 1 ml Trizol reagent (Ambion). The homogenate was
transferred to a clean RNAse free 1.5 ml microtube and 100 µl of BCP (MRC)
was added and the sample was vortexed. The tube was centrifuged at 4°C at
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13k RPM (15g) for 10 min. The aqueous phase (400 µl) was removed and
precipitated with 200 µl of 200 proof ethanol. The mixture was placed into a
filter insert and centrifuged at 13k RPM for 20 seconds. The supernatant was
discarded and the filter unit was washed twice with 500 µl of wash solution
(RiboPure Kit, Ambion). The sample was eluted in 100 µl of elution buffer
(RiboPure) and immediately mixed with 350 µl of Lysis buffer (RNAqueous Kit,
Ambion). 250 µl of 200 proof ethanol was added and mixed. The sample was
applied to a new filter insert and centrifuged at 13k RPM for 20 seconds. The
sample was washed twice with 500 µl of 80% ethanol and eluted in 100 µl of
elution solution (RNAqueous) and quantitated using UV/Vis absorbion at 260
nm. The 260/280 ratio was consistently above 1.7, signifying very little protein
contamination. 2 µg of RNA was used to make cDNA using the High Capacity
cDNA kit (Applied Biosystems) on a Bio-Rad C1000 thermocycler. 40 ng of
cDNA was used for each individual gene expression using Taqman based
amplification on an ABI 7500 Fast system using the default Standard protocol.
Mouse Taqman probes used were: Gapdh, Ifna2, Ifnb, Cramp, Il6, Tnfa,
Il23p19, Il12p35, Il12p40, Il22, Il17a, Vegfa, Vegfb, Egf and Ifng (Table 3).
Human Taqman probes used were: Gapdh, Ifna2, and Ifnb (Table 4).
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Primer
Beta defensin 1
Beta defensin 2
Beta defensin 3
Beta defensin 4
Beta defensin 14
chemerin
CRAMP
Egf
Gapdh
IFN-a
IFN-b
IFN-g
IL6
IL12p35
IL12p40
IL17A
IL-22
IL23p19
TNF-a
Vegf-a
Vegf-b

Assay I.D.
Mm00432803_m1
Mm00657074_m1
Mm04214158_s1
Mm00731768_m1
Mm00806979_m1
Mm00503579_m1
Mm00438285_m1
Mm00438696_m1
Mm99999915_g1
Mm00833961_s1
Mm00439552_s1
Mm00801778_m1
Mm00446191_m1
Mm00434165_m1
Mm01288991_m1
Mm00439619_m1
Mm00444241_m1
Mm00518984_m1
Mm00443258_m1
Mm00437304_m1
Mm00442102_m1

Table 3. Mouse Taqman Primers. Taqman primers generated
by Applied Biosystems for the indicated genes are provided as
well as their unique sequence ID.
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Primer
IFN-a
IFN-b
Gapdh

Assay I.D.
Hs02621172_s1
Hs01077958_s1
Hs03929097_g1

Table 4. Human Taqman Primers. Taqman primers generated
by Applied Biosystems for the indicated genes are provided as
well as their unique sequence ID.
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PDC ISOLATION AND IN VITRO STIMULATION
pDCs were isolated from spleens of 6-12 week female BALB/cJ mice using the
pDC Isolation Kit II (Miltenyi Biotec) with a purity of > 90%. 50,000 cells were
cultured overnight in RPMI based media (10% FCS, 50 µM beta mercapto
ethanol, pen/strep, glutamine, sodium pyruvate, Hepes). The supernatants were
used to determine Interferon-α protein secretion using a commercial Elisa kit
(PBL). As a source of DNA, we used synthetic phosphodiesteric CpGcontaining oligonucleotides, hybridized to its complementary strand to mimic
natural mammalian DNA fragments. 0.3 µM dsDNA was mixed with 30 µM
cathelicidin peptides in a volume of 20 µl for 30 minutes at RT.
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CHAPTER 3
PDCS INFILTRATE SKIN INJURY
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TAPE STRIP INJURY MODEL

To establish an injury model we focused on the endogenous response rather
than the aggregate stimuli encompassing both host driven injury mediators and
external triggers of immunity (e.g. bacterial cell components, virus’ or other
environmental factors). Our aim was to elucidate the immune response to a
“sterile injury.” Most wound studies employ full thickness injuries wherein a
dermal biopsy punch is applied across the epidermis into and through the
dermis. This method was unsuitable for my research as it completely breaches
the skin barrier and exposes the skin to foreign immunogens. To this end we
primarily utilized an epidermal stripping approach in which the outer layers of
the epidermis, composed of flattened anuclear keratinocytes, is removed
through use of cellophane tape. Tape stripping not only removes cells of the
epidermis but also kills keratinocytes at the epidermal/dermal border which form
the basement membrane.

Unlike the full thickness injury model, the basement membrane cells remain
intact, although transepidermal barrier functionality is breached and a marked
increase in transepidermal water evaporation occurs. However, the damaged
basement layer generates a danger signal and activates the wound healing
response. Tape stripping using 20 strokes across the dorsal flank of shaven
and depilated Balb/c mice results in acute erythema (Figure 4) characterized by
a large but transient increase in cellularity in the underlying dermis (Figure 5).
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Pathologically, the bulk of cellular infiltration occurs at 24 to 48 hours
characterized by dense granularity. By 72 hours to 5 days post injury, the
basement membrane is replaced by a new keratinocyte layer which further
differentiates to form flattened anuclear layers characteristic of the stratified
epidermis (Figure 6).
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Figure 4. Tape strip model. Murine epidermis before and
after tape stripping with 20 strokes of cellophane tape
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Dermal cells (x106)
per cm2
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4
2
0

0

24
48
Time (h)

72

Figure 5. Tape stripping induces strong dermal
infiltration. Dermal cell suspensions isolated from skin
at various times after injury and viable cells were
counted. The mean number of cells ± SEM per cm2 of
injured skin is given and represent data from five
independent mice over a 3-day time course.
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0h - injury

24h - inflammatory response

48h - crust formation

72h - re-epithelialization

Figure 6. Sterile epidermal injury prompts a rapid and transient leukocyte
infiltrate in the dermis which precedes epithelial repair. Frozen sections of
injured skin were stained with H&E to identify infiltrating cells. There are few
dermal cells in nascent injured skin. However, by 24h a strong inflammatory
response can be seen. By 48h there is strong granulation tissue formation in the
epidermis characterized by a thick crust like appearance. By 72h, the injured
epidermis is repaired by migrating keratinocytes which proliferate to form a new
stratified layer.
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SKIN INJURY INDUCES A RAPID INFILTRATION OF PDCS

Mice were shaven, depilated, tape stripped and sacrificed at various time points
including 6, 24, 48, and 72 hours. The injured skin was excised and a single cell
suspension was generated using a Dispase/Collagenase treatment scheme.
Cells were stained for leukocyte populates with fluorescent-labeled antibodies
and analyzed by flow cytometry. Interestingly, there was a large but transient
increase in pDCs (B220+PDCA1+) after injury (Figure 7 A). Remarkably, the
infiltration was brief as pDC levels returned to pre-injury levels by 48 hours. The
pDC population was co-stained for MHC Class II (IA/IE), CD11c, and Siglec H
to confirm pDC phenotype (IA/IElowCD11c+Siglec-H+, Figure 7 B). Moreover,
the B220+PDCA1+ population lacked expression of common myeloid markers
CD3, CD11b, and CD19 (data not shown). Additionally, immunohistological
staining of Siglec H (3H3 clone) of injured skin at 24h confirmed leukocyte
morphology (Figure 7 C).

NEUTROPHILS INFILTRATE SKIN INJURY EARLY WHILE T CELLS
INFILTRATE LATER

Concomitant with pDC infiltration there was a large and robust neutrophil (Gr1+CD11b+) infiltration at 24 hours (Figure 8). Surprisingly, the bulk neutrophil
infiltrate was gone by 48 hours, mirroring pDC kinetics. However, there was a
delay in T cell (CD3+) infiltration (Figure 9). There was a substantial baseline T
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cell population (17%) in the skin which increased to 55% by 48 hours and was
back to baseline levels by 72 hours. Similarly, there was a resident population
of conventional dendritic cells (mDC, CD11c+CD11b+PDCA1-) which did not
show an increase but rather decreased in population after injury (Figure 10).
The mDC baseline population was gradually restored by 48 hours. Cumulative
experiments are shown depicting infiltration time course kinetics of pDCs,
neutrophils, and T cells (Figure 11).

SKIN INJURY INDUCES TRANSIENT INCREASE IN TYPE I IFN AND PROINFLAMMATORY CYTOKINES

pDCs are the main producers of IFN-α/β, so we sought to investigate whether
Type I IFN were involved in wound repair. Tape stripped mice were euthanized
and skin was harvested at 6, 24, 48, and 72 hours. Pre-injury skin was used as
a baseline control. Excised skin was stored in RNAlater until RNA was
extracted. RNA was isolated from skin using a specialized protocol (see
Materials and Methods).

Gene expression for IFN-α, IL-6, and TNF-α was performed. There was a rapid
but transient induction of IFN-α with peak expression at 24 hours which
paralleled maximal pDC skin infiltration. IL-6 expression peaked at 6 hours with
significant expression at 24 hours before returning to baseline levels.
Neutrophils are known to be early producers of IL-6 and have been reported to
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infiltrate skin as early as 3 hours after injury. TNF-α expressed reached
maximum levels at 48 hours before declining. It has been reported that
neutrophils are the chief TNF-α producers during the first 48 hours after injury
whereas monocytes/macrophages are take over TNF-α production after 48
hours.
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Figure 7. Rapid infiltration of pDCs into injured skin. (A) The
percentage of pDCs (B220+PDCA-1+) in dermal single cell suspensions
isolated from injured skin was measured by flow cytometry. Representative
flow cytometry plot of pDC in injured skin over a 3-day time course. The
percentage of each population is shown in the plots. (B) Flow cytometry for
CD11c, IA/IE, Siglec H surface expression on B220+PDCA-1+ pDC 24
hours after skin injury. (C) Representative immunohistochemical staining
for Siglec H in injured skin collected 24 hours after tape stripping.
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54

0h

48h

14%

55%

72h
17%

CD3

17%

24h

Figure 9. T cell infiltrate injured skin later than pDCs and neutrophils. The
percentage of T cells (CD3+) in dermal single cell suspensions isolated from
injured skin was measured by flow cytometry. Representative flow cytometry
plot of neutrophils in injured skin over a 3-day time course. The percentage of
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Figure 12. pDCs are transiently activated to produce type I IFNs in
injured skin. Time course analysis of IFN-α, IL-6 and TNF-α mRNA tissue
expression in injured skin. The data are given as fold induction over time 0
and represent the mean ± SEM of five mice per timepoint.
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CHAPTER 4
PDCS ARE ACTIVATED IN SKIN INJURY TO
PRODUCE TYPE I IFNS
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PDCS ARE ACTIVATED TO PRODUCE TYPE I IFN

To determine whether pDCs were the main producers of IFN-α seen in skin
injury, pDCs were depleted using a BST depleting antibody cocktail composed
of a-PDCA1 (Miltenyi) and mAB 927 (kind gift from Marco Colonna, Figure 13).
Similar effects in skin were observed. Neutrophils were depleted using a Ly6G
specific antibody (1A8 clone, Bioxcel). 500 µg of each pDC depleting antibody
was injected, intraperitoneally, at -48 and -24 hours prior to tape stripping. 1 mg
of α-Ly6G antibody was applied, intraperitoneally, -24 and -4 hours prior to tape
stripping. Depleted and control (whole rat IgG) injected mice were tape stripped
and the skin was excised 24 hours later. Gene expression was performed using
Taqman chemistry. Complete inhibition of IFN-α was observed in pDC depleted
mice (Fig 14) with no significant reduction in neutrophil depleted mice.
Additionally, IL-6 but not TNF-α gene expression was significantly reduced in
pDC depleted mice. Conversely, TNF-α was significantly reduced in neutrophil
but not pDC depleted mice (Figure 14).

PDC ARE ACTIVATED TO PRODUCE TYPE I IFN THROUGH NUCLEIC
ACID RECOGNITION PATHWAY

Next we wanted to determine whether pDC activation was induced through TLR
recognition of nucleic acids that are released from dead and dying cells in the
injured tissue. First we evaluated Type I IFN signaling in tape stripped MyD8860

deficient mice. MyD88 is a downstream adapter molecule of both TLR 7 and
TLR 9 receptor signaling (114). TLR 7 recognizes single strand RNA and TLR 9
is responsible for single and double stranded DNA recognition (114). MyD88deficient mice were tape stripped and gene expression analysis was performed
on injured skin at 24 hours after injury. Remarkably, both IFN-α and IFN-β
gene expression were suppressed in MyD88-deficient mice signifying that pDC
activation was Toll-Like Receptor dependent. To further elucidate the roll of
nucleic acids in providing the stimulus for pDC activation in skin injury we
injected Balb/c mice with IRS 954, a combined a TLR-7/9 inhibitory compound
(115, 116). IRS 954 is a phosphorothioate oligodeoxynucleotide molecule
whose sequence, 5'-TGC TCC TGG AGG GGT TGT-3' is capable of mediating
both TLR 7 and TLR 9 suppression (115). TLR 7 suppression occurs through
the 5’-TGC sequence whereas TLR 9 suppression derives from the adjacent
TCC TGG AGG GGT TGT-3' sequence. IRS 954 or saline control was injected
24 and 6 hours prior to tape stripping. Consistent with the MyD88-deficient mice
data, IRS 954 was capable of completely abrogating both IFN-α and IFN-β
gene expression following skin injury. These data conclusively demonstrate that
infiltrating skin pDC are activated through TLR engagement of nucleic acids.

Skin injury is marked by dying keratinocytes which release genomic nucleic acid
into the extracellular space. To understand whether infiltrating skin pDC
activation is RNA, DNA or both RNA/DNA mediated we evaluated Type I IFN
gene expression in TLR7-deficient and TLR 9 inhibitor treated mice after tape
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strip injury. The specific TLR 9 inhibitor IRS 869, 5'-TCC TGG AGG GGT TGT3', was used (116). IRS 869 or saline control was injected 24 and 6 hours prior
to tape stripping. IFN-α and IFN-β gene expression was significantly reduced in
TLR7-deficient mice (Figure 16 A). Additionally, pretreatment of IRS 869
reduced both IFN-α and IFN-β gene expression following injury (Figure 16 B).
These data demonstrate that pDC activation is mainly driven through TLR 7
engagement and that RNA is the predominant nucleic acid mediating such
activation.

Furthermore, the pro-inflammatory cytokine, IL-6 gene expression was
significantly repressed in MyD88-deficient and IRS 954 treated mice following
injury (Figure 17 A and B) whereas TNF-α gene expression was unaffected by
TLR 7/9 abrogation. Similar responses were observed in TLR7-deficient and
IRS 869 treated mice (Figure 18 A and B). These data corroborated our
observations made in pDC depleted mice (Figure 14) which showed strong IFNα and IL-6 reduction.
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Figure 14. pDCs are transiently activated to produce type I IFNs in
injured skin. Relative IFN-α, IL-6 and TNF-α mRNA tissue expression of
uninjured skin or injured skin collected 24 hours after tape stripping of either
pDC-depleted, neutrophil-depleted, or control IgG treated mice. Data
represent the mean ± SEM of five mice per group. *, P= 0.001; **, P= 0.02;
***, P< 0.001, unpaired Student’s t test.
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Figure 16. pDCs sense nucleic acid through TLR 7 and TLR 9 in injured
skin. (A) Relative IFN-α and IFN-β mRNA tissue expression of uninjured skin
or injured skin collected 24 hours after tape stripping of TLR7-/- or control
mice. Data represent the mean ± SEM of four mice. *, P= 0.01; **, P= 0.02,
unpaired Student’s t test. (B) Relative IFN-α and IFN-β mRNA tissue
expression in uninjured skin and injured skin (24h) of mice pretreated with
saline or 100 µg of TLR 9 inhibitor IRS 869. Data represent the mean ± SEM
of seven mice.
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Figure 17. IL-6 and TNF-α
α cytokine mRNA expression in injured skin of
MyD88-deficient and TLR 7/9 inhibitor treated mice. (A) Relative IL-6 and
TNF-α mRNA tissue expression of uninjured skin or injured skin collected 24
hours after tape stripping of MyD88-/- or control wild-type mice. Data
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CHAPTER 5
CATHELICIDINS ACTIVATE PDCS BOTH IN
VITRO AND IN VIVO
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CATHELICIDINS ARE EXPRESSED UPON SKIN INJURY

Host derived-nucleic acids released by damaged cells are normally inert but
can be converted into triggers of TLR7 and TLR9 in the presence of the human
cathelicidin peptide LL-37 (30, 29). We therefore sought to determine whether
the murine cathelicidin ortholog of LL-37, called CRAMP, is induced in our skin
injury model. The expression of CRAMP mRNA in mouse skin was not
detectable prior to injury, but was rapidly induced upon tape stripping, reaching
a peak at 24 hour and declining thereafter (Figure 19 A). This time course
closely paralleled the infiltration of pDCs into injured skin and their activation to
produce IFN-α/β, suggesting a potential role of cathelicidins in breaking innate
tolerance to self-nucleic acids injured skin.

MURINE CATHELICIDIN BIND NUCLEIC ACIDS

Next, we wanted to evaluate whether CRAMP could bind dsDNA. In our
previous work (30, 29) we demonstrated that LL-37 efficiently binds dsDNA and
RNA and can activate human pDC to produce robust levels of IFN-α. We
developed a technique to measure the efficiency of peptide binding to nucleic
acid utilizing an ultra-sensitive fluorescent DNA binding probe. PicoGreen
fluorescent dye, which predominantly binds to dsDNA, is excited at 480 nm and
has primary emission spectra at 520 nm. The principle of the assay is that DNA
bound to peptides are inaccessible to PicoGreen binding. Hence, strong
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peptide-DNA interactions lead to lower fluorescence whereas weak peptideDNA interactions do not decrease the high DNA-PicoGreen fluorescence.
CRAMP at various concentrations: 0.01 µM, 1 µM, 50 µM and 100 µM were
mixed with 3 µg/ml dsDNA for 30 min and analyzed for complex formation.
PicoGreen was added to each mixture and PicoGreen fluorescence emission
was measured. CRAMP was able to bind DNA at 1 µM with increased binding
to 100 µM of CRAMP (Figure 19 B).

CRAMP-DNA COMPLEXES ACTIVATE PDCS TO PRODUCE IFN-α
α

Finally, to investigate whether CRAMP-DNA complexes could activate murine
pDCs, we isolated fresh splenic pDCs using a negative magnetic beads
approach (pDC Isolation Kit II, Miltenyi). 50,000 pDCs (>90% purity) were
stimulated overnight with either DNA alone, CRAMP alone, or DNA mixed with
CRAMP. As a control we also used a scrambled form of CRAMP alone or
mixed with DNA. We found that only DNA mixed with CRAMP induced IFN-α
production in pDCs (Figure 19 C).
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Figure 19. Cathelicidin gene expression is upregulated in injury and
Cathelicidin peptide induces pDC activation to produce IFN-α
α. (A) Time
course analysis of cathelicidin mRNA tissue expression in injured skin. The
data are given as fold induction over time 0 and represent the mean ± SEM
of four mice per timepoint. (B) Cathelicidin-DNA binding studies using 3
ug/ml dsDNA and 0.01, 1, 50 or 100 uM cathelicidin peptide using
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produced by purified splenic pDC after overnight stimulation with either DNA
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scCRAMP plus DNA. Data are representative of two independent
experiments, error bars represent the SEM of triplicate wells. *, P=0.001.
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IN VIVO INJECTED CRAMP PROMOTES PDC INFILTRATION AND
ACTIVATION TO PRODUCE TYPE I IFNs

To test whether CRAMP would also break innate tolerance to nucleic acids and
activate pDCs in vivo, we injected CRAMP, scrambled CRAMP or saline into
mouse skin. We found that CRAMP but not the scrambled peptide or saline
injection induced a rapid and transient infiltration of pDCs and the expression of
IFN-α/β (Figure 20 A and B). These findings indicate that CRAMP is sufficient to
break innate tolerance to induce activation of pDCs to produce IFN-α/β in skin
in vivo.

CRAMP IS SUFFICIENT BUT NOT REQUIRED FOR PDC INFILTRATION IN
SKIN INJURY

To determine whether CRAMP is necessary for pDC activation to injured skin,
we tape-stripped the skin of cathelicidin-deficient mice (112) and analyzed gene
expression for IFN-α/β. Surprisingly, we found that IFN-α and IFN-β produced
by pDCs were still induced in injured skin even in the absence of cathelicidins
(Figure 21). Thus, cathelicidins are sufficient but not necessary to break innate
tolerance to nucleic acids and induce IFN-α/β production by pDCs in injured
skin.
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ADDITIONAL MOLECULES MAY MEDIATE PDC INFILTRATION TO
INJURED SKIN

It is possible that there is a redundant signaling pathway which can mediate
pDC infiltration and activation in the skin. Other antimicrobial peptides such as
the beta-defensins have been shown in human psoriasis to be overexpressed in
involved tissue (105,107). To investigate whether beta-defensins may play a
role in skin injury we performed gene expression analysis for mouse betadefensins -3, -4, and -14 which correlate to human beta-defensins -2, -3, and 4. As a control, we analyzed mouse beta-defensins -1, and -2 which have been
shown to be expressed under homeostasis and are downregulated upon injury
(Figure 22). Interestingly, we found that beta-defensin-3, -4, and -14 were all
upregulated upon injury which indicate that pDC may be activated through
nucleic acid-Beta-defensin complexes.

Alternatively, chemerin has recently been shown to play a pivotal role in pDC
recruitment to the skin especially in psoriasis (117). We analyzed chemerin
gene expression in injury skin and found a drastic increase in chemerin gene
expression (Figure 22).
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Figure 22. Select mouse beta-defensin (mBD) antimicrobial peptides as
well as Chemerin are expressed during skin injury. mBD-3 and mBD-4,
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CHAPTER 6
PDCS AND TYPE I IFNS PROMOTE
INFLAMMATORY RESPONSES AND WOUND
HEALING IN INJURED SKIN
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PDCS DRIVE EXPRESSION OF DC, TH1 AND TH17 CYTOKINES

Because pDCs are potent stimulators of immune responses through their
production of IFN-αβ, we next sought to investigate the role of pDCs in the
induction of inflammatory responses in injured skin. We found that, along with
IL-6 and TNF-α (Figure 14), skin injury induced a rapid expression of DCderived cytokines IL-12 and IL-23, TH1 cytokine IFN-γ, and TH17 cytokines IL17 and IL-22 (Figure 23 A), but not IL-4 or IL-10 (not shown), reaching a peak
between 24 and 48 hours after injury. pDC depletion, which reduced the
expression of IL-6 in injured skin (Figure 14), was also found to decrease the
expression of IL-12 and IL-23 (Figure 23 A). Intriguingly, pDC depletion was
found to profoundly inhibit the induction of IL-17 and IL-22 without affecting the
expression of IFN-γ (Figure 23). These findings demonstrate that skin-infiltrating
pDCs play an important role in the induction of inflammatory immune responses
in injured skin, in particular the induction of IL-6 and TH17 cytokines.

PDCS ARE REQUIRED FOR EFFICIENT RE-EPITHELIAZATION

Since the inflammatory process is directly linked to the wound healing
response, we next sought to determine whether pDCs also play a role in the reepithelialization of tape stripped skin. Keratin 6 (K6), expressed by early
differentiating and proliferating keratinocytes but not by fully differentiated
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Figure 23. pDCs participate in the inflammatory response of skin wound
healing. Relative IL-23p19, IL-12p35, IL-17A, IL-22, and IFN-γ mRNA tissue
expression of uninjured skin or injured skin collected 24 hours after tape
stripping of either pDC-depleted or control IgG treated mice. Data represent the
mean ± SEM of five mice per group. *, P= 0.03; **, P= 0.05; ***, P= 0.04,
unpaired Student’s t test.
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keratinocytes, was used as a marker to quantify re-epithelialization of skin
wounds (118). In normal mice, K6-positive keratinocytes appeared 24 hours
after injury and repopulated the entire injured skin surface within 72 hours
(Figure 24 A). In pDC depleted mice, K6-positive keratinocytes appeared only
around 72 hours (Figure 24 B) and complete re-epithelialization lagged behind
control mice by three days (not shown). These data indicate that the infiltration
of pDCs in skin wounds plays a key role in promoting early wound reepithelialization. To confirm these data we adopted another skin injury model, in
which a full-thickness skin defect is placed by a 3 mm punch biopsy and the
wound closure is measured over time. Similarly, pDC-depleted mice showed a
significant delay in wound closure when compared to control mice, (Figure 24
C).

TYPE I IFN PROMOTE EFFICIENT RE-EPITHELIAZATION AND INDUCE DC
AND TH17 CYTOKINES

To determine the role of pDC-derived IFN-αβ in wound healings, we used IFNαβ-receptor-deficient mice and repeated similar experiments performed with
pDC-depleted mice. Like pDC-depleted mice, IFN-αβ-receptor-deficient mice
showed a significant delay in wound re-epithelialization (Figure 25 A) and
displayed a profound deficiency in IL-6, IL-17 and IL-22 expression levels in
injured skin (Figure 25 B). A similar deficiency of IL-6, IL-17 and IL-22
expression was observed in MyD88-deficient mice. These data suggest that the
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ability of pDCs to trigger early inflammatory responses and promote wound
repair is related to their nucleic acid mediated TLR activation and production of
IFN-αβ.
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Figure 24. pDCs participate in the re-epithelialization of skin wound healing.
(A) Representative time course of Keratin 6 (K6) expression in injured skin
measured by immunofluorescence. (B) Percentage of K6 expression in injured
skin in pDC-depleted and control IgG treated mice. Data represent the mean ±
SEM of five mice per group. *, P= 0.01; **, P= 0.05, unpaired Student’s t test. (C)
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Data in (A)-(C) are representative of at least two independent experiments.
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Figure 25. Type I IFNs participate in the re-epithelialization of skin wound healing.
(A) Percentage of K6 expression in injured skin in IFNAR-/- or control mice. Data
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84

PDCS DO NOT AFFECT ANGIOGENESIS

To evaluate whether pDCs also participated in other processes of wound
healing in addition to re-epithelialization we measured angiogenesis related
markers. We evaluated endothelial cell activity using CD31 as a marker for
neovasculature. CD31 also known as PECAM-1 is highly expressed by
endothelial cells and is also weakly expressed by periperhal lymphoid cells.
Importantly, CD31 is down regulated by neutrophils upon extravasation from
circulation. pDC-depleted mice did not show reduced CD31 expression
compared to control mice in tape stripped mice (Figure 26). Additionally, we
performed gene expression for Vegfa, Vegfb, and Egf, key genes involved in
angiogenesis in pDC-depleted mice to determine whether pDCs may exert an
effect upstream from endothelial cell proliferation. However, we did not observe
any significant differences between pDC-depleted and control mice in
expression of these genes (Figure 27).
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Figure 26. pDCs do not affect endothelial cell activity.
Percentage of CD31 expression in the skin (epidermal/dermal
border area) of injured control or pDC-depleted. Data represent
the mean ± SEM of five mice per group.
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HUMAN SKIN INJURY INDUCES PDC INFILTRATION AND EXPRESSION
OF TYPE I IFNS

To determine whether pDCs also infiltrate and sense human skin wounds, we
performed skin biopsies in healthy human volunteers prior and 24 hours after
tape stripping. Immunohistochemistry for BDCA2, a specific marker for human
pDCs, revealed that large numbers of pDCs infiltrate human skin 24h after
mechanical injury (Figure 28). We also found a significant induction of IFN-α
mRNA expression in injured skin (Figure 29 A), suggesting that pDCs are
activated to produce IFN-α similar to our finding in the murine models. We also
confirmed these data in another model of skin injury induced by Sodium Lauryl
Sulfate (SLS) treatment, which induces a chemical disruption of the epidermal
barrier by perturbing the lipid bilayer structure in the stratum corneum, leading
to damages to the basal keratinocytes (119). Like mechanical-induced skin
injury, this chemical induced skin injury induced rapid pDC infiltration and
significant induction of IFN-α mRNA expression in injured skin (Figure 28,
Figure 29 B).
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Figure 28. Human skin injury induces rapid infiltration of pDCs.
Representative immunohistochemical staining of human skin for the
pDC-specific marker BDCA2 reveals absence of pDCs in normal
skin prior to injury (upper left panel), the rapid infiltration of pDCs in
injured skin by tape stripping (upper right and lower left panels) or
by treatment with SLS (lower right panel), scale bar: 10 µM. The
data are representative of at least five independent healthy
individuals.
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Figure 29. Human skin injury induces rapid infiltration of pDCs and their
activation to produce IFN-α. (A) Quantification of BDCA2-positive pDC
numbers in human skin before and 24 hours after tape stripping of five
independent healthy individuals (left panel). Relative IFN-α mRNA tissue
expression in healthy human skin before and 24 hours after tape stripping
(right panel). Each symbol represents an independent donor. *, P= 0.05; **,
P= 0.03, unpaired Student’s t test. (B) Quantification of BDCA2-positive pDC
numbers in human skin before and 24 hours after chemical injury with SLS of
five independent healthy individuals (left panel). Relative IFN-α mRNA tissue
expression in human skin before and 24 hours after chemical injury with SLS
of at least 7 independent healthy individuals (right panel). Each symbol
represents the independent individual. *, P= 0.04; **, P<0.001, unpaired
Student’s t test.
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Injury is the most common assault that an organism must confront. It is vital to
the existence of the host to limit exposure of compromised tissue in order to
avoid infection as well as to limit inflammatory mediated tissue destruction.
Mammalian systems have evolved a very highly ordered repair process to heal
wounds. The process is very intricate and the efficiency is dependent upon
many factors such as the health status of the host, nature and scope of the
injury, and most importantly, the degree of pathogen inoculation. Many aspects
of skin injury have been characterized over the past few decades, yet many
processes are not yet understood. We know from the past decade of skin
research that keratinocytes play a much more dynamic role in maintaining
homeostasis than just by providing a barrier to the external environment.

Keratinocytes play a vital immunological role in maintaining barrier protection as
well as sensing injury and alerting the body of problems. In fact, it has recently
been shown that keratinocytes can “sense” bacteria through TLR expression
which can then elicit an antimicrobial response (120). Keratinocytes are armed
with evolutionary conserved defense peptides which can kill bacteria directly
through perturbing the cell wall resulting in lysis. Moreover, the cathelicidin
antimicrobial peptide can act as in a chemotactic fashion and has been shown
to recruit neutrophils, T cells, and macrophages to the skin (121-123).
Furthermore, injured keratinocytes release growth factors and pro-inflammatory
cytokines such as IL-1β, IL-8, IL-6, and TNF-α (105-107). Recently our group
has uncovered a novel role for keratinocyte-derived cathelicidin in activating
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pDCs through association of cathelicidin with self-nucleic acid (29, 30). These
studies suggest that keratinocytes may work in concert with other cell types in
both initiating an immune response as well as eliciting an effective barrier
against pathogen infection.

pDCs provide a unique role in immunity. On one hand they are capable of
promoting a strong inflammatory response through generation of vast amounts
of Interferon alpha in response to viral pathogens. On the other hand, they can
promote tolerance through induction of ICOSL and interaction with ICOS+
expressing T cells (124). Typically pDCs lack efficient mechanisms to uptake
and bear MHC Class II antigens but they can cross-present antigens via MHC
Class I. Additionally, pDCs originate from the lymphoid lineage unlike other
dendritic cells which are myeloid derived. Many functions of pDC have been
well characterized such as robust viral sensors, peripheral tolerance, MHC
cross-presentation and most notably, producers of high Type I Interferon levels.

pDCs lack the ability to recognize specific molecules but instead are armed to
recognize evolutionarily conserved patterns such as prokaryotic DNA, viral
proteins, etc. This ability enables pDCs to be one of the early sensors of viral
infection. However, the exact nature of pDC activity in non-infectious roles has
scarcely been evaluated. Here, we demonstrate a novel but logical role for pDC
in detecting skin injury.

This study was driven by the observation that in

psoriasis, pDCs are present in the early lesion. Studies by Gilliet and others
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have shown that pDCs are in fact early infiltrators and initiators of the psoriatic
lesion. Remarkably, pDCs promote inflammation as well as mediating the
recruitment and activation of mDC and T cells. However, the trigger of pDC
infiltration into the skin as well as the stimulus for pDC activation has not been
elucidated. Coupled with the recent observations that pDCs can become
activated to produce large amounts of IFN-α in response to self-DNA
associated with the self-skin peptide, LL-37, along with the findings that LL-37 is
released by keratinocytes in psoriasis we desired to understand the
physiological role of pDCs in normal wound healing.

There is scant evidence for a physiological role for pDCs in injury response.
Moreover, there have been conflicting reports on the effect of Type I IFN in
promoting more efficient wound repair. To this end, we developed an murine
injury model based on the study by Sano which utilized tape stripping the dorsal
flank of mice with constitutive expression of Stat3 (125). In that study, the
authors observed increased dermal inflammation in as little as 12 hours. In our
experiments, taped stripped mice exhibited a strong inflammatory infiltrate
characterized by abundant and transient levels of pDCs and neutrophils.
Interestingly, both pDCs and neutrophils were absent by 48 hours. It is well
known that neutrophils infiltrate injury (tape stripping, full-thickness, and burn)
early with maximal infiltration lasting up to 3 days. pDCs are absent in skin
under homeostatic conditions in mice whereas they constitute a very minor
population in human.
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Evidence of pDCs playing a role in a physiological setting prompted us to
examine their functional role in wound healing. First, we observed that Type I
IFN gene expression was upregulated transiently after injury. Furthermore, IFNα gene expression studies in wild type, pDC-depleted, MyD88-deficient, and
TLR7-deficient demonstrated that pDCs were the primary source of IFN-α. Proinflammatory genes were evaluated to understand the exact contributions of
pDC in the injured skin. Interestingly, IL-6 was significantly pDC dependent
while TNF-α was unaffected by pDC depletion. On the other hand, neutrophils
contributed the bulk of TNF-α while exerting modest effects on IL-6 production.
Previous studies have shown that IL-6-deficient mice have severe defects in
wound

healing,

in

particular,

delayed

re-epithelialization,

impaired

angiogenesis, and reduced macrophage infiltration (126).

TLR signaling through MyD88 was requisite for pDC activation. This finding is
line with the known molecular recognition pathway for pDC which selectively
express TLR 7 and TLR 9. Furthermore, in a recent skin injury study, MyD88deficient mice exhibited delayed wound contraction, decreased and delayed
granulation tissue formation, and reduced new blood vessel density (127). Our
recent studies that demonstrated pDC activation through cathelicidin/nucleic
acid associated complexes fully supports the notion that in vivo skin infiltrating
pDC can sense these complexes to trigger endosomal activation of TLRs to
produce IFN-α. Intriguingly, studies performed in TLR7-deficient mice
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demonstrated that TLR 7 may be the preferred mechanism of MyD88 signaling
as there was very little induction of IFN-α and IFN-β after injury. However, TLR
9 signaling may also be important in pDC activation in skin injury. Our studies
directed at the role of TLR 9 signaling were limited to the use of TLR 9 specific
inhibitor. Although, no significant differences in IFN-α and IFN-β gene induction
between control and inhibitor treated mice were observed in these mice we
cannot rule out the possibility that the inhibitor was not applied at the optimal
time or was ineffective. Moreover, TLR9-deficient mice were recently found to
be unable to induce Type I IFN responsive genes (in press). Additional research
efforts should be directed at probing the dynamic contributions of TLR 7 and
TLR 9 signaling in greater detail in order to fully understanding the molecular
basis of pDC activation in skin injury.

Mechanisms underlying pDC infiltration and activation in skin injury were
evaluated to understand how pDCs potentially can provoke inflammation in
psoriasis. Previously we showed that, in human, pDCs can produce robust
levels of IFN-α upon stimulation with mammalian DNA complexed with the
human cathelicidin peptide, LL-37. This mechanism may be responsible for
pDC activation during a psoriatic episode in which a surface wound triggers
keratinocytes to produce LL-37. Damaged cells may release DNA which can
complex with LL-37 and provide a potent stimulus for pDC activation. I
confirmed our earlier findings which demonstrated the ability of LL-37 to bind to
nucleic acid in mice using the CRAMP, the murine ortholog of LL-37. CRAMP
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was capable of binding murine DNA although requiring higher molar
concentrations to fully quench PicoGreen fluorescence compared to LL-37.

Additionally, when complexed with DNA, CRAMP was able to induce significant
amounts of IFN-α protein from fresh splenic murine pDCs. Moreover,
intradermally injected CRAMP was able to solicit a strong pDC infiltrate to the
skin in vivo compared to controls (PBS and scrambled CRAMP). Gene
expression studies from CRAMP-injected mice revealed strong Type I IFN
induction. CRAMP is clearly capable of mediating a strong pDC response in
vivo. Although CRAMP was injected without associated DNA, DNA released
from cells damaged by the injection may provide DNA necessary to bind to the
injected CRAMP. CRAMP is not however the sole player responsible for pDC
activation, as mice deficient in cathelicidin produced similar levels of both IFN-α
and IFN-β upon tape stripping.

pDC infiltration and activation in skin injury is unlikely to be driven by
autoantibodies and the formation of immune complexes, as we did not find an
increase in anti-nuclear antibodies after skin injury (not shown). Candidate
factors that trigger this process are HMGB1 (128), heat shock proteins (129)
and other cationic antimicrobial peptides as they are all expressed in damaged
skin and they have the ability to form self-nucleic acid-containing complexes
that activate pDCs. Investigations by others have demonstrated that additional
AMPs belonging to the beta defensin family are involved in skin defense and
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are upregulated upon injury. We investigated gene expression of five betadefensins (beta defensins 1-4, 14) shown to be important in skin defense.
Importantly, some of these defensins in humans have been shown to bind DNA
and activate pDC (beta defensin 3, 4, 14). In mice, beta defensin 3, 4 and 14
were all upregulated upon injury and may potentially provide additional stimuli
for pDC infiltration and activation in injured tissue. Further evaluations of the
ability of beta defensins to induce pDC infiltration and activation in vivo need to
be conducted as well as the consequence of their deficiency using knockout
models.

Recent investigations in psoriasis have uncovered Chemerin, a novel
chemokine substantially expressed during peak pDC activity. pDC migration to
the skin has been attributed to the effect of chemerin, an agonist for chemokine
like receptor 1 (CMKLR1) specifically expressed by pDCs (117, 130, 131).
Chemerin is constitutively expressed in healthy skin by endothelial cells and
fibroblasts as an inactive propeptide that requires activation through C-terminal
cleavage by serine proteases. It is possible that during skin injury the release of
proteases by damaged keratinocytes allows the formation of the active
chemerin that recruits pDCs to the injury site. In addition, skin injury induces the
expression of CXCR3-ligands (not shown), a set of chemokines which are
typically induced in structural cells of the skin as a result of IFN-α/β expression
and which have been shown to promote recruitment pDCs into sites of their
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activation (132). Evaluation of chemerin in our model showed a strong induction
of Chemerin which persisted for at least 3 days post injury.

To investigate whether pDCs were exerting its effects on wound healing
through Type I IFN we analyzed wound healing responses in tape stripped IFNα/β receptor knockout mice (IFNAR-/-). Recent reports investigating the use of
exogenous IFN-α applied topically to full-thickness injuries have resulted in
mixed conclusions (133, 134). Pammer et al. found that 1000 IU/ml of human
recombinant IFN-α2b (INTRON-A or ROFERON) was able to inhibit apoptosis
of endothelial cells, in vitro, but induced senescence upon continued treatment
(133). However, Bhartiya et al observed that 20,000 Units (murine) injected
intramuscularly over a 5 day time course in both full-thickness and incisional
injuries enhanced re-epithelialization and increased fibroblast migration to the
wound bed (134). No studies have evaluated the role of IFN-α, neither using
physiological levels of IFN-α, nor have looked at physiologically produced IFNα. In gene expression studies we found that Type I IFN was important for IL-6
induction. Similarly, both pDC-depleted and IFNAR-/- mice induced significantly
lower amounts of IL17A and IL22 mRNA transcripts. However, there was one
main exception, IL23p19 and IL12p35 gene induction was significantly reduced
in pDC-depleted but not IFNAR-/- mice. This striking finding suggests that pDCs
contribution to wound healing is much more dynamic than simply producing
Type I IFNs.
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As mentioned in the introduction wound healing is comprised of four
overlapping phases. Phase one involves triggers hemostasis involving both the
release chemotactic and pro-inflammatory molecules by keratinocytes and
platelet activation. pDCs infiltrate the injury during the second phase
(inflammatory phase). Therefore, we examined whether pDCs played a role in
downstream injury responses. Phase three consists of neo angiogenesis to
supply damaged skin nutrients and oxygen vital for tissue repair. Injured skin
was stained for CD31, a marker for endothelial cells, to see whether abrogation
of the pDC response impaired angiogenesis. No differences in CD31
expression were observed suggesting that pDCs do not influence endothelial
cell division. Moreover, gene expression for angiogenic markers Vegfa, Vegfb,
and Egf did not reveal any differences throughout a 5 day time course between
wt and pDC-depleted mice. Phase 3 also includes matrix remodeling which
consists of metalloprotease activity to remove the fibrin clot and collagen
synthesis to provide a structured dermis was evaluated. No differences in
Mmp3, Mmp8 and Mmp9 gene expression were observed. pDCs do not
contribute to angiogenesis or matrix remodeling.

Phase four of wound healing encompasses the mobilization of keratinocytes to
re-epithelialize the injured epidermis. Re-epithelialization characterized by
migration of keratinocytes from both the wound edge and hair follicles to form a
new basal layer was evaluated to evaluate the overall effects of wound healing.
We utilized K6 expression as a surrogate marker for re-epithelialization. K6 is
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expressed by early hyperproliferating keratinocytes and is downregulated upon
after a new basement membrane is generated. Interestingly, both pDC-depleted
and IFNAR-/- mice demonstrated delayed wound healing compared to control
mice. Wound healing defects persisted through day 3 post injury and eventually
resolved by day 5 (data not shown). Additionally both pDC-depleted and
IFNAR-/- mice exhibited reduced wound closure after full-thickness injuries.
These data show that both pDCs and Type I IFN are important in resolving skin
injury. However, the nature of pDC contributions to wound healing independent
of Type I IFN is not fully understood.

pDCs may potentially exert their influence in wound healing through
keratinocyte mobilization. Keratinocytes from the wound edge are required to
detach

anchoring

attachment

molecules

such

as

desmosomes

from

neighboring cells and migrate to the injured tissue to form a new basement
membrane. This process involves both mitogenic and proliferative cues.
Potentially pDC act on keratinocytes ability to navigate through and across the
fibrin clot. Keratinocytes upregulate proteolytic enzymes necessary for their
movement across the injured tissue. Once they reach the denuded epidermis
keratinocytes must proliferate in order to re-establish both the basement
membrane as well as the the stratum corneum. As evidenced by K6 which is
expressed only by early hyperproliferating keratinocytes, keratinocytes rapidly
undergo proliferation when they form a new basal layer. In my studies, the most
pronounced effect on pDC depletion was compromised K6 expression. Future
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studies evaluating the role of pDC and Type I IFN should be performed to
determine whether keratinocyte mobility and proliferative ability are affected.

Our investigation was directed at understanding the role of pDCs in a
physiologically relevant process which may influence potential therapeutic
strategies for skin disorders such as psoriasis, melanoma, and burn trauma. We
evaluated whether pDCs, in addition to being present in murine skin injury, were
present in human skin injury. pDCs infiltrated both mechanical (tape stripped)
as well as chemical (Sodium Lauryl Sulfate) mediated human skin injury.
Moreover, pDCs in both conditions were activated to produce substantial levels
of IFN-α and IFN-β mRNA. These results demonstrate that pDCs response to
injury is potentially an evolutionarily conserved response to both aid in injury
recovery as well as to potentially thwart a pathogenic response. Whether pDCs
were programmed to respond only to danger cues such as host cell degradation
products or viral antigens it is clear that pDCs participate in non-infectious
related processes.

Another striking result of our studies was that pDC involvement in wound
healing is important for upregulation of cytokines vital for T cell differentiation
into TH17 cells. IL-23 is a heterodimeric cytokine composed of p19 and p40
subunits. p19 is exclusive to IL-23 while p40 is shared with IL-12. IL-23 has
been shown to be important in host inflammatory response to infection. In
addition to being important in driving CD4 T cell differentiation to TH17 cells, IL-
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23 also promotes the upregulation of MMP9 (important for keratinocyte
mobilization through granulation tissue) and angiogenesis (107). IL-23 in
combination with IL-6 and TGF-β1 drives differentiation of CD4 T cells into
effector TH17 cells which secrete IL-17 and IL-22. Interestingly, abrogation of
pDC response to wound healing significantly impaired IL23p19, IL17A, and IL22 gene induction. No evidence suggests that pDCs produce IL23p19 directly.
So the likely mechanism is that pDC activation induces a bystander response,
possibly by resident mDC, to induce IL-23 gene expression. Another important
observation that we made was that IL23p19 gene induction was not suppressed
in IFNAR-/- mice suggesting an IFN-α/β independent mechanism. IL-23 injected
into the skin of mice was found to induce psoriasis features such as erythema,
acanthosis, dermal inflammatory infiltrates, dermal papillary blood vessels and
IL-22 dependent psoriasisform changes.

pDCs also affect the production of TH17 cytokines, as the induction of IL-17
and IL-22 is abrogated in pDC-depleted mice. This is in line with recent studies
showing that pDCs can drive the differentiation of IL-17 and IL-22-producing T
cells (135-137), and that IL-6 is implicated in this process (135). IL-22 appears
to be particularly important in epidermal regeneration as this cytokine directly
promotes keratinocyte migration and proliferation (138-140). Surprisingly, mice
deficient in IFN-α/β-receptors display a similar inhibition in IL-6 and TH17
cytokine induction with delayed re-epithelialization of skin wounds. Because
IFN-α/β are potent stimulators of immune responses but do not exert a direct
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activity on keratinocytes (141), these findings suggest that IFN-α/β in skin
wounds promote epidermal regeneration and wound repair through the
induction of TH17-biased inflammatory responses. The exact mechanism that
links IFN-α/β production to pDC-mediated TH17 responses is still unclear.
However, there is additional evidence that IFN-α/β produced by pDCs drives
TH17 responses and epidermal proliferation in a therapeutic model of skin
treated with the TLR 7 agonist imiquimod (142). Furthermore, IFN-α/β produced
by pDCs triggers psoriasis (93), a disease characterized by large numbers of
pathogenic TH17 cells that trigger epidermal hyperproliferation (143).

Our studies were centered on understanding what role, if any, pDCs play in a
normal wound assault in the skin at aims of further understanding why and how
pDCs facilitate psoriasis pathogenesis. We have uncovered a novel role for
pDCs in wound healing and future efforts should be directed at understanding
both chemotactic and regulatory cues involving pDC infiltration and activation in
skin injury. A broader appreciation for the role of keratinocytes in immunological
settings could be useful in understanding pDC function. Keratinocytes produce
pro-inflammatory cytokines in addition to antimicrobial peptides which may be
important for pDC activity. TH17 cells may provide a positive feedback loop
which acts on keratinocytes to further release cationic antimicrobial peptides.
Sustained activation of pDCs by cationic antimicrobial peptides complexed with
extracellular nucleic acid may lead to a dysregulated response resulting in
chronic inflammation. Psoriasis does have a genetic component which may
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increase the susceptibility for an uncontrolled inflammatory response to injury.
This continued cycle may be involved in the initiation of a psoriatic lesion.

Many questions regarding the mechanisms of pDC infiltration and regulation as
well as the role of pDC induced IL-23, IL-17, and IL-22 gene expression in skin
injury remain. Future efforts at determining mediators of pDC infiltration to
wounded skin should encompass the following molecules: chemerin, the
CXCR3 ligands; CXCL9 (Mig), CXCL10 (IP-10), and CXCL11 (ITAC), and the
CXCR4 ligand, CXCL12 (SDF-1). Chemerin is highly expressed in wounded
skin as well as in psoriasis. Moreover, pDCs express CMKLR1, the cognate
receptor for chemerin. Additionally, CXCL9, CXCL10, and CXCL11 are all
expressed by dermal resident cells, are highly expressed in psoriasis and can
be recognized by pDCs. Finally, CXCR3 requires cooperative CXCR4
engagement of CXCL12 for pDC trafficking.

We showed that the AMP, CRAMP, was able to mediate pDC infiltration to the
skin and activate pDC. Yet, CRAMP-deficient mice produced equivalent levels
of IFN-α and IFN-β mRNA upon skin injury. Potentially, CRAMP works in
concert with additional AMP to mediate pDC infiltration and activation in skin
injury. We have shown that additional cationic AMPs, beta-defensins -3, 4, and
14, are all elevated in injured skin. It is important to screen these beta-defensins
when complexed with nucleic acid for the ability to activate purified splenic
pDCS to produce IFN-α. Beta-defensins found to be able to activate pDCs
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should then be injected, intradermally, to determine their ability to mediate pDC
infiltration and activation in vivo. Beta-defensins that can mediate pDC
infiltration and activation should be evaluated in a targeted gene knockout
setting. Ideally CRAMP-deficient mice would be crossed with beta-defensindeficient mice to determine whether complete type I IFN signaling is abrogated.
Such a finding would lead to better therapeutic strategies for psoriasis in which
cathelicidin and beta-defensins are both targeted.

Another important question is how pDCs and type I IFNs contribute to reepithelialization. Our studies implicate delayed keratinocyte mobilization to the
injury. However, mechanisms underlying this are poorly understood. Potentially,
pDCs and type I IFNs influence the detachment of migrating keratinocytes from
basement membrane or promote the proliferation of leading edge keratinocytes.
Alternatively, pDCs and type I IFNs promote the migration of keratinocytes
across the provisional matrix, which requires upregulation of MMPs and specific
integrin expression. These possibilities should be explored in further detail.

Regulation of pDC activity in skin injury needs to be investigated. Some
important questions are why is pDC activity transient? What mechanisms
balance continued inflammation versus tolerance? How is this mechanism
subverted in psoriasis?
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Finally, it is important to understand the role of pDC induced IL-23, IL-17, and
IL-22 gene expression in skin injury. Skin injury experiments using IL-23, IL-17,
and IL-22-deficient mice can shed light on the role of these cytokines in wound
healing. Potentially, these TH17 related cytokines are upregulated in
preparation of an infection.

In conclusion, our study identifies a role of pDCs in recognizing nucleic acids
released in injured skin and promoting early inflammatory responses and reepithelialization of the wounds. These findings provide a paradigm shift in
understanding the function of pDCs from the classical view of a specialized cell
type in the recognition of viral infections to important sensors of tissue damage
at epithelial surfaces.
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